Rapport Therapeutics, Inc.
RAPP
$11.43
$0.0450.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -125.11% | -- | -- | -- | |
| Total Depreciation and Amortization | 649.11% | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 211.01% | -- | -- | -- | |
| Change in Net Operating Assets | -191.10% | -- | -- | -- | |
| Cash from Operations | -138.50% | -- | -- | -- | |
| Capital Expenditure | -47.00% | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -117.21% | -- | -- | -- | |
| Cash from Investing | -115.75% | -- | -- | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 294,540.74% | -- | -- | -- | |
| Repurchase of Common Stock | -34,750.00% | -- | -- | -- | |
| Issuance of Preferred Stock | -55.99% | -- | -- | -- | |
| Repurchase of Preferred Stock | 66.28% | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 100.00% | -- | -- | -- | |
| Cash from Financing | 52.70% | -- | -- | -- | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -134.13% | -- | -- | -- | |